Methods for treatment of growth disorders

A method for treating a subject having insulin-like growth factor-1 deficiency (IGFD) comprising;

• administering to a human pediatric subject suffering from a growth disorder characterized by insulin-like growth factor-1 deficiency (IGFD) and partial endogenous growth hormone (GH) signaling an amount of insulin like growth factor-1 (IGF-1) effective to promote growth in the subject, wherein the subject is further characterized as follows:
• the subject, at the time of treatment or prior to initial treatment with IGF-1, has or had a height at least about 2.0 standard deviations (SD) below a normal mean for a subject of the same age and gender, and
• the subject has or had a blood level of IGF-1 below, but not more than about 2 SD below, normal mean levels for a subject of the same age and gender,
• and wherein the subject receives IGF-1 in a single administration per day.

A method for treating a partial endogenous growth hormone activity or signaling growth disorder in a subject, comprising

• administering to a human pediatric subject suffering from a growth disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor (IGF-1) effective to promote growth in the patient, wherein the patient is further characterized as follows:
• the subject, at the time of treatment or prior to initial treatment with IGF-1, has or had a height at least about 2.0 standard deviations (SD) below a normal mean for a subject of the same age and gender,
• the subject has growth hormone (GH) levels in blood that are normal or elevated for a subject of the same age and gender, and
• the subject has insulin-like growth factor-1 (IGF-1) levels in blood that are below, but no more than about 2 SD below, normal mean IGF-1 blood levels for a subject of the same age and gender,
• and wherein the subject receives IGF-1 in a single administration per day.

A method for treating an endocrine disorder in a patient, comprising

• administering to a human adult patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor (IGF-1) effective to improve metabolism in the patient, wherein the patient is further characterized as follows:
• the patient has growth hormone (GH) levels in blood that are normal or elevated for a subject of the same age and gender,
• the patient has insulin-like growth factor-1 (IGF-1) levels in blood that are below, but no more than about 2 SD below, normal mean IGF-1 blood levels for a subject of the same age and gender, and
• the patient had suffered from a growth disorder during childhood, wherein at the time of treatment or prior to initial treatment with growth promoting therapy, the patient had a height at least about 2 standard deviations (SD) below a normal mean for a subject of the same age and gender, and had an endocrine system capable of growth hormone (OH) induction of IGF-1 and IGFBP-3,
• and wherein the patient receives IGF-1 in a single administration per day.

A method for treating an endocrine disorder in a patient, comprising

• administering to a human adult patient suffering from an endocrine disorder characterized by partial endogenous growth hormone activity or signaling an amount of insulin-like growth factor (IGF-1) and an amount of growth hormone that in combination are effective to improve metabolism in the patient, wherein the patient is further characterized as follows:
• the patient has growth hormone (GH) levels in blood that are normal or elevated for a subject of the same age and gender,
• the patient has insulin-like growth factor-1 (IGF-1) levels in blood that are below, but no more than about 2 SD below, normal mean IGF-1 blood levels for a subject of the same age and gender, and
• the patient had suffered from a growth disorder during childhood, wherein at the time of treatment or prior to initial treatment with growth promoting therapy, the patient had a height at least about 2 standard deviations (SD) below a normal mean for a subject of the same age and gender, and had an endocrine system capable of growth hormone (GH) induction of IGF-1 and IGFBP-3,
• wherein the patient receives IGF-1 in a single administration per day, wherein the patient receives growth hormone in a single administration per day, and wherein the single administration of growth hormone and the single administration of IGF-1 are administered to the patient substantially contemporaneously each day.